Evidence map›Paper›PMID 35285804›Full record

Trial reportEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2022

Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.

Robbert J de Winter, Azfar Zaman, Hironori Hara, Chao Gao, Masafumi Ono, Scot Garg, Pieter C Smits, Pim A L Tonino, Sjoerd H Hofma, Raul Moreno and 7 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02870140 (A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the SUPRAFLEX Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
65.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02870140 nacompletednot on this map

A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the SUPRAFLEX Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

TypeinterventionalSponsorECRI bvRan2016 to 2020Enrolled1,435ConditionsCoronary StenosisArmsSUPRAFLEX, XIENCE
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 7 countries.

Robbert J de WinterAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Azfar ZamanNewcastle Freeman Hospital, Newcastle University, and Newcastle upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom.
Hironori HaraAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Chao GaoDepartment of Cardiology, National University of Ireland Galway, Galway, Ireland.
Masafumi OnoAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Scot GargDepartment of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom.
Pieter C SmitsMaasstad Ziekenhuis, Rotterdam, the Netherlands.
Pim A L ToninoDepartment of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Sjoerd H HofmaMedical Centre Leeuwarden, Leeuwarden, the Netherlands.
Raul MorenoCardiology Department, La Paz University Hospital, Madrid, Spain.
Anirban ChoudhuryDepartment of Cardiology, University Hospital of Wales, Cardiff, United Kingdom.
Ivo PetrovAcibadem City Clinic Cardiovascular Center, Sofia, Bulgaria.
Angel CequierBellvitge University Hospital, University of Barcelona, IDIBELL, Barcelona, Spain.
Antonio ColomboInvasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
Upendra KaulAcademics and Research, Batra Hospital and Medical Research Center, New Delhi, India.
Yoshinobu OnumaDepartment of Cardiology, National University of Ireland Galway, Galway, Ireland.
Patrick W SerruysDepartment of Cardiology, National University of Ireland Galway, Galway, Ireland.
Ollscoil na Gaillimhe – University of Galway · IERadboud University Nijmegen · NLAcibadem City Clinic · BGAmsterdam University Medical Centers · NLBatra Hospital and Medical Research Centre · INBellvitge University Hospital · ESHospital Universitario La Paz · ESHumanitas University · ITMaasstad Ziekenhuis · NLMedisch Centrum Leeuwarden · NLNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRoyal Blackburn Teaching Hospital · GBUniversity Hospital of Wales · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the TALENT study, the sirolimus-eluting ultrathin strut Supraflex stent was non-inferior to the XIENCE stent for a device-oriented composite endpoint (DoCE: defined as cardiac death, target vessel myocardial infarction [TV-MI], or clinically indicated target lesion revascularisation [CI-TLR]) at 12 months.

aimsThis study investigated the 3-year outcomes of the TALENT trial and long-term impact of ultrathin drug-eluting stents (DES), compared to the XIENCE everolimus-eluting thin stent.

methodsThe TALENT trial is a prospective, multicentre, randomised all-comers trial comparing the Supraflex sirolimus-eluting stent with the XIENCE everolimus-eluting stent, with planned follow-up for 3 years.

resultsThe TALENT trial enrolled 1,435 patients (Supraflex n=720, XIENCE n=715) with 3-year follow-up data available in 97.8% in the Supraflex group, and in 98.9% in the XIENCE group. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, TV-MI or CI-TLR. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). In a meta-analysis of long-term follow-up (3-5 years), ultrathin strut DES tended to reduce DoCE (relative risk 0.89 [0.79-1.01]; p=0.068), compared to thicker strut DES. The risks for cardiac death and definite or probable stent thrombosis were similar between ultrathin strut DES and thicker strut DES.

conclusionsAt 3-year follow-up, the use of the Supraflex stent was at least as safe and efficacious as the XIENCE stent in an all-comers population. CLINICALTRIALS: gov: NCT02870140.

Indexed as

Drug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionThrombosisDeathEverolimusHumansProspective StudiesSirolimusStentsTreatment OutcomeEverolimusSirolimus

Identifiers

PMID35285804
PMCPMC10241281
OpenAlexW4221089858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.